Parvus is pioneering a novel class of disease-modifying therapeutics – Navacims™ – that represent a paradigm shift in the way that autoimmune diseases are treated. Current approaches generally require broad suppression of the immune system to prevent immune attack against a patient’s own tissues. In contrast, our Navacim drug candidates are able to selectively blunt the action of pathogenic immune cells (including cytotoxic T cells and antigen-presenting cells), thereby restoring immune tolerance and potentially reversing disease.
Parvus has entered into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture, and commercialize novel Navacim™ therapeutics for the treatment of inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac disease (CD).
Parvus has shown in multiple preclinical in-vivo models of autoimmune disease that its Navacims can reprogram disease- or tissue-specific cells to orchestrate reversal of disease, as published in leading peer-reviewed journals. Based on the Company’s broadly enabling therapeutic platform, Parvus has generated a robust R&D pipeline and is advancing several proprietary Navacim development candidates toward clinical testing.
Parvus Therapeutics Announces Key Executive and Board of Directors AppointmentsRead More
Parvus Therapeutics Publication of Preclinical Proof-of-Concept Research that Underlies the Development of Navacim™ Therapeutics for the Treatment of Autoimmune Liver DiseasesRead More
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune DiseasesRead More